reference/21402915

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/21402915

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase II\|Journal Article\|Randomized Controlled Trial
endingPage	586
issn	1532-1827 0007-0920
issueIdentifier	5
pageRange	581-586
publicationName	British Journal of Cancer
startingPage	581
bibliographicCitation	Eisen T, Ahmad T, Flaherty KT, Gore M, Kaye S, Marais R, Gibbens I, Hackett S, James M, Schuchter LM, Nathanson KL, Xia C, Simantov R, Schwartz B, Poulin-Costello M, O'Dwyer PJ, Ratain MJ. Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. British Journal of Cancer. 2006 Aug 01;95(5):581–6. doi: 10.1038/sj.bjc.6603291.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_215e4709c2beb519684b9bc3cdd60056 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_bfd99e0f2bc819ed8e6cb4da12ef3a10 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7a99520ed01ead7076113526475e3932 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ef688c63a1b8225aa4fbea69c9ac5c07 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3c59fed7db3ba2936a44922457e90e98 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d65dba4d996d653289b48c40569455f0 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_fabc4e6dce628b23ce1759a175cc09e4 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ab19d889b87a4339937d850a5a651e3c http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8aa03c131a67d0eab25fb36c256c4cf9 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_320ac8c67be504184140db5d6bd334f1 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_00334c6e620d1e4df37175f6c87b7a56 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c6273c0608d3be83f83c44820ee55a50 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_276d7f9ff8436b0eb39c755c2a4126a7 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_878bf28f88ca48230f301fa90a9899e0 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_453c89aba1be4b4c475492debe06ab1d http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_02801cf4adf88291ffed68423c792b2b http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_20e188adc21d973b4524e47ac99ad030
date	2006-08-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://pubmed.ncbi.nlm.nih.gov/PMC2360687 https://doi.org/10.1038/sj.bjc.6603291 https://pubmed.ncbi.nlm.nih.gov/16880785
isPartOf	http://rdf.ncbi.nlm.nih.gov/pubchem/journal/1765 https://portal.issn.org/resource/ISSN/0007-0920 https://portal.issn.org/resource/ISSN/1532-1827
language	English
source	https://scigraph.springernature.com/ https://www.crossref.org/ https://pubmed.ncbi.nlm.nih.gov/
title	Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis
discusses	http://id.nlm.nih.gov/mesh/M0328153 http://id.nlm.nih.gov/mesh/M0016578 http://id.nlm.nih.gov/mesh/M0002336 http://id.nlm.nih.gov/mesh/M0029573 http://id.nlm.nih.gov/mesh/M0446095 http://id.nlm.nih.gov/mesh/M0014833 http://id.nlm.nih.gov/mesh/M0027090 http://id.nlm.nih.gov/mesh/M0018233
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D020533Q000627 http://id.nlm.nih.gov/mesh/D011725Q000627 http://id.nlm.nih.gov/mesh/D008545Q000188 http://id.nlm.nih.gov/mesh/D001557Q000627
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D008875 http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D020533Q000633 http://id.nlm.nih.gov/mesh/D011905 http://id.nlm.nih.gov/mesh/D010671 http://id.nlm.nih.gov/mesh/D009536Q000031 http://id.nlm.nih.gov/mesh/D017931 http://id.nlm.nih.gov/mesh/D012449 http://id.nlm.nih.gov/mesh/D048493Q000235 http://id.nlm.nih.gov/mesh/D009367 http://id.nlm.nih.gov/mesh/D016133 http://id.nlm.nih.gov/mesh/D000369 http://id.nlm.nih.gov/mesh/D008545Q000235 http://id.nlm.nih.gov/mesh/D008297 http://id.nlm.nih.gov/mesh/D000328 http://id.nlm.nih.gov/mesh/D000077157 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D008545Q000473 http://id.nlm.nih.gov/mesh/D008545Q000098 http://id.nlm.nih.gov/mesh/D011725Q000633 http://id.nlm.nih.gov/mesh/D000368 http://id.nlm.nih.gov/mesh/D001557Q000633
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7660 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_1c50845b337a3c11fa194521642a3ec8 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID216239 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_606d6234a2cf2e2d52b0ade7ed869ca5 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8448

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127830723 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID673 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID135808554 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128611606 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128865459

Total number of triples: 83.